Applied Filters
Buyers of Zetia seek class recertification after 4th circ ruling
Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
Pfizer targets Eucrisa generics in five Delaware suits
Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.
Zoetis sues rival over generic pet vomiting treatment
Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.
Lawmakers urge USPTO to curb IPR denials under Fintiv
Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.
Allergan closes the book on Fetzima generics suit
Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima.
FDA urges USPTO to tackle rising drug costs
The US Food and Drug Administration has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.
Pfizer to settle Xeljanz suit with Teva
Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Teva drops lawsuit with Amicus over Creates Act dispute
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.
Endo International can’t stop Vasostrict generic
The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.
Second Circuit says Takeda can’t dodge two antitrust suits
The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.
